Flexibility and Scalability for the Next Frontier of Multiomics

With rapid advancements in multiomics, we’re standing on the brink of a drug development revolution for all. There is a clear departure from the one-size-fits-all paradigm as the world advances into a new era of personalized medicine. Our industry is speeding through this transitional time, and it’s essential to make sure the tools we use to craft the future are flexible, adaptable, and accessible in this ever-changing landscape. At Element, our goal is not just to serve these purposes today but also drive progress tomorrow and every day after.?

Twenty-five years ago, the prevailing thought in the emerging genomics industry was that DNA held the ultimate answers to human health – a master key to understanding and addressing our most pressing medical challenges. Following the successful efforts to map the human genome, the focus shifted toward RNA as a new pathway for potential breakthroughs. Today, we recognize the true frontier lies in integrating multiomic readouts, and the tools we currently possess are only scratching the surface of true biological complexity.?

In my seven years with Element, and decades as a scientist, one lesson stands out: the challenges we face today are rarely the challenges of tomorrow. At Element, we’re deliberate in how we lay our future roadmap, making each decision with a commitment to the innovative spirit.??

This is why I’m personally excited about our new AVITI24 system, which exists to excel at solving today’s problems, but also has the flexibility and scalability to help solve the problems of the future. Anticipating the next frontier is a challenge that I know keeps us all up at night, and a key to tackling it will be instruments ready to empower researchers with flexibility, scalability accessibility, and accuracy across a multiomics space.??